Blogs

Be the first person to recommend this.
To Dr. John Hansen, every patient was special. “Every patient that I’ve known, every patient that I’ve helped … every one of them is a precious experience,” Hansen said in an interview in 2018 . Hansen, 76, died peacefully at his home on July 31 after a battle with pancreatic cancer. Hansen left a huge mark on the bone marrow transplant community, with one of his most notable contributions being the National Marrow Donor Program, now known as Be The Match. He played an integral role in understanding how to find suitable donors for each transplant patient, establishing registries of these donors and started collections of biological samples and data that ...
0 comments
Be the first person to recommend this.
Dr. Wesley Miller was quiet at times, but when he did speak, he was worth listening to. “He was an excellent listener,” said Dr. John Bantle, one of Miller’s close friends, and a former colleagues at the University of Minnesota. “He was extremely insightful and the definition of integrity. If he got into something, he didn’t do anything halfway. He did it intensively.” Miller passed away peacefully at his home on July 15 at the age of 71 after a battle with cancer. Miller was considered a pioneer at the University of Minnesota for his work in bone marrow and stem cell transplantation. He worked there for more than 40 years and was an early proponent of ...
0 comments
Be the first person to recommend this.
On Aug. 8, ASTCT President Navneet Majhail, MD, MS, submitted a letter to the Director of Coverage and Analysis Group at the Centers for Medicare and Medicaid Services Tamara Syrek Jensen, JD. In it, Majhail lauded CMS for their Decision Memo on CAR T-cell Therapy for Cancers. From Majhail's letter:  "The American Society for Transplantation and Cellular Therapy (ASTCT) is very pleased with the recent coverage announcement from The Centers for Medicare and Medicaid Services (CMS) in the Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG- 00451N). The Society appreciates the opportunity to work closely with the Agency on this National ...
0 comments
Be the first person to recommend this.
The ASTCT Pharmacy Special Interest Group (SIG) Program Planning and Education Committees have launched the Online Enduring Case Presentations from this year's ASTCT Pharmacists Conference. This joint venture is a benefit provided to those practicing in hematopoietic cell transplant (HCT) who are seeking continuing education, but were unable to attend the 2019 TCT Meetings of ASTCT and CIBMTR or missed the ASTCT Pharmacists Conference. If interested, please see below for more information. Courses (FACT credit available) : Evolving Treatment Options for AML by Dr. Lydia Benitez, PharmD, BCOP How I Treat Steroid-Refractory Acute GVHD by Dr. Amin Alousi, ...
0 comments
Be the first person to recommend this.
By Mikaela VanMoorleghem, FACT Education and Training Coordinator Help FACT Design Education Just for YOU   We would like to hear from YOU! FACT wants to provide the education that you need. Please help us develop education that is tailored to fit your needs by filling out this short 3-question survey. Complete the  Education Suggestions  survey. -- Biology of Blood and Marrow Transplantation Publishes Article on FACT Clinical Outcome Review Process The journal Biology of Blood and Marrow Transplantation (BBMT) has electronically published the article, Integration of Publicly Reported Center Outcomes into Standards and Accreditation: ...
0 comments
Be the first person to recommend this.
In this month’s Pharmacy SIG Literature Update:  PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation, high-dose bendamustine and melphalan conditioning for patients with multiple myeloma, a mortality analysis of letermovir prophylaxis for CMV and much more! Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion. ***        Must read. Landmark publication that affects practice **           Recommend reading. Secondary paper that adds to literature *             Consider reading. Cursory ...
0 comments
Be the first person to recommend this.
Updates from CMS ASTCT and the American Society of Hematology had a joint call with members of CMS’ Hospital and Ambulatory Policy Group to reiterate our recommendations to improve payment for CAR-T therapy in FY 2020 and to share our early thinking about how to reimburse equitably for the therapy in FY 2021 and beyond. Dr. Dianna Howard, co-chair of the new ASTCT Government Relations Committee, participated in the call and shared the challenges they are facing at Wake Forest establishing a CAR-T program because of the institution’s concerns about reimbursement. We expect CMS to release the final FY 2020 Inpatient Prospective Payment System rule in early ...
0 comments
Be the first person to recommend this.
At academic medical institutions in the USA, July tends to be hectic as they welcome a fresh crop of residents and fellows. Most of our incoming hematology-oncology fellows have not had any exposure to BMT or cell therapy during residency, which is a rather unfortunate reality of the how our current internal medicine training is structured nationwide. Our team provides an “Orientation to BMT/cell therapy” session where we talk about navigating the BMT rotation and managing common issues they may need to address when on call. I take advantage of their naivety by telling them that if they don’t review and sign off on our program SOP’s on time, "our program will ...
0 comments
2 people recommend this.
By Akshay Sharma, MBBS -- St. Jude Children's Research Hospital As I was flying over the Rocky Mountains on my late afternoon Delta flight, enjoying the views of the snow-covered peaks and skiing trails below, I did not know that the next few days were going to be one of the most transformative experiences of my transplant career so far. I had been to a few clinical research courses in the past and they all were great and educational in their own unique ways. But none of the one’s that I had attended previously had been in particular career a defining one. As I landed in Salt Lake City Airport and was waiting for some of my course mates to arrive, ...
0 comments
Be the first person to recommend this.
By Darren Johnson, PA-C - The Children's Hospital at TriStar Centennial, Sarah Cannon Research Institute I was in a fog, all I could see was darkness although it was the middle of the day, the blinds were open and all the lights in my room were on. The nurses around me were hectic, moving quickly and clearly with purpose. Beside me, my mom was squeezing a bag of IV fluid. I was just trying to keep up, but I was scared and I couldn’t process all the activity. I gathered every bit of energy and focus I had to ask one question: “Am I going to die today?” “NO!” was the resounding answer from my nursing staff (including my mom) and that was enough for me.I ...
0 comments
Be the first person to recommend this.
The ASTCT would like to thank Dr. Miguel Perales for all of his work on the ASTCT Practice Guidelines App. Physicians from all over the world are using the app to improve the care provided to transplant patients. The mobile app has been downloaded close to 5,700 times by clinicians in 46 different countries. It was because of Dr. Perales's vision that we were able to launch the app. It is through his efforts, and those of other society volunteers, that we are able to add new tools and information on a regular basis. We also want to thank Seattle Genetics for their continued support of this tool.  Download the app in iTunes:  https://apps.apple.com/us/app/astct-practice-guidelines/id1204871675 ...
0 comments
Be the first person to recommend this.
Have you been watching HBO this spring? No we are not talking about Game of Thrones, but something much more pertinent to the cellular transplant community. HBO released a five episode mini-series about the 1986 Chernobyl disaster. If you have not seen it - it's worth watching. It is an accurate and chilling reminder of what can happen as a result of a radiological disaster. In the US since 2001, there has been an intense emphasis on preparing the US for a similar radiological disaster which could result in casualties who could develop Acute Radiation Syndrome and would require care by the members of ASTCT. One organization working to help prepare the nation ...
0 comments
Be the first person to recommend this.
We had a major quality incident in June – at our home. It was 9 p.m. on a Wednesday night and we were heading home from Olive Garden after a nice dinner celebrating the last day of school. As my better half was reviewing the schedule for the following day, we realized we had no plan for childcare! We had assumed that our 17-year-old would be available and willing to perform older sisterly duties for a day – that is, keep her two younger brothers safe and fed and prevent a riot by keeping them separated for 10 hours. But she reminded us that she had a full day commitment that Thursday and was not going to be home, and that she had texted us about this a week ...
0 comments
Be the first person to recommend this.
ASTCT’s FY2020 IPPS Proposed Rule Response On June 24 th , ASTCT submitted comments to the Centers for Medicare and Medicaid (CMS) on the FY2020 Hospital Inpatient Prospective Payment System (IPPS) proposed rule. ASTCT’s comments respond to both the proposals put forth by CMS as well as the request for comment on certain items. Some of the recommendations ASTCT made to the agency include: ASTCT supports CMS’ proposal to increase the new technology add-on payment (NTAP) for all new technologies, but recommends that the agency increase the percentage from 50 percent to 80 percent rather than 65 percent as proposed for all NTAPs. ASTCT recommends that ...
0 comments
Be the first person to recommend this.
In this month’s Pharmacy SIG Literature Update:  Maintenance therapies for Hodgkin and Non-Hodgkin lymphomas, autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents, prophylactic low-dose azacitidine and donor lymphocyte infusions for high-risk acute myeloid leukemia and myelodysplastic syndrome and much more! Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion. ***        Must read. Landmark publication that affects practice **           Recommend reading. Secondary paper that adds to literature ...
0 comments
Be the first person to recommend this.
By Mikaela VanMoorleghem, FACT Education and Training Coordinator FACT Events at ISCT Were a Success! Chrissy Gordon: A Patient Perspective FACT was honored to have its Cellular Therapy and Cord Blood Inspection and Accreditation Workshop in Melbourne, Australia opened by Ms. Chrissy Gordon, a recipient of an unrelated bone marrow transplant in 2000. Chrissy’s inspirational story of diagnosis, treatment, transplant, challenges, and successes over the past twenty years highlighted the importance of continuing to pursue improvements in the quality of patient care and advancing the promising developments in the field of cellular therapy.  Diagnosed ...
0 comments
Be the first person to recommend this.
More than 25 years ago, a group of physicians, scientists, clinicians and researchers came together. They had one mission in mind: As blood and marrow transplantation was growing and evolving as a field in the early 1990s, there were growing concerns about how it would be regulated. The FDA had announced its regulatory approach to bone marrow transplantation, and leaders in the field wanted to be ahead of the curve.  “There was a strong belief that the professionals in the field should be setting the standards, not the regulators,” said Dr. Phyllis Warkentin, FACT’s chief medical officer and one of the founding members.  The newly-formed ASBMT (now known as ...
0 comments
Be the first person to recommend this.
2019 ASTCT SIG Pharmacy New Investigator Research Award Purpose   The ASTCT Pharmacy New Investigator Award is designed to encourage clinical, laboratory/ translational medicine, pharmacoeconomic, or health services research by young investigators in the field of blood and marrow transplantation.     The award, $25,000 per year for two years, may be used for direct support of research costs and/or to support the investigator’s salary for his or her research effort.     Eligibility   To be eligible for the New Investigator Award, the applicant must be a licensed pharmacist (PharmD) who has completed ≥2 years of postdoctoral ...
0 comments
Be the first person to recommend this.
2019 ASTCT SIG Pharmacy New Investigator Research Award Request for Letter of Intent (LOI)   Interested applicants for the ASTCT Pharmacy SIG New Investigator Research Award are required to submit a Letter of Intent (LOI). The LOI should follow the format below and will serve to permit assessment of eligibility for the award.   Letters of Intent must be received by e-mail to the administrator of the grant, no later than Friday, July 12, 2019 (5:00 pm CST).   Please submit electronically as a single PDF file to Angie Dahl (adahl@astct.org) the Grant Liaison.   ASTCT Pharmacy SIG Research Committee Angie Dahl, Grant Liaison adahl@astct.org ...
0 comments
Be the first person to recommend this.
By Mikaela VanMoorleghem, Education and Training Coordinator,  Foundation for the Accreditation of Cellular Therapy Prepare for the NetCord-FACT International Cord Blood Standards, Seventh Edition By: Andra Moehring, MHA, FACT Standards Development Manager The Seventh Edition NetCord-FACT International Cord Blood Standards for Collection, Banking, and Release for Administration  will be published on October 15, 2019 and will become effective on January 15, 2020. Programs currently pursuing renewal or initial accreditation under the Sixth Edition Standards must remain mindful of these dates and ensure timely submission of pre-inspection materials ...
0 comments